Sanofi Drops Acquisition of Maze’s Pompe Disease Drug After FTC Challenge

Sanofi on Monday announced it is abandoning a proposed licensing agreement with California biotech Maze Therapeutics, targeting the rare, genetic and often fatal disorder Pompe disease, in response to an FTC administrative complaint and authorization for a lawsuit in federal court.